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Abstract
Aims: Deleted in liver cancer 1 (DLC1), a member of RhoGTPase activating protein (GAP) family, is known to have
suppressive activities in tumorigenicity and cancer metastasis. However, the underlying molecular mechanisms of how
DLC1 suppresses cell motility have not been fully elucidated. Rho-kinase (ROCK) is an immediate down-stream effector of
RhoA in mediating cellular cytoskeletal events and cell motility. In the present study, we aimed to investigate the effects of
DLC1 on Rho/ROCK signaling pathway in hepatocellular carcinoma (HCC).
Methodology/Principal Findings: We demonstrated that DLC1 negatively regulated ROCK-dependent actomyosin
contractility. From immumofluorescence study, we found that ectopic expression of DLC1 abrogated Rho/ROCK-mediated
cytoskeletal reorganization including formation of stress fibers and focal adhesions. It also downregulated cortical
phosphorylation of myosin light chain 2 (MLC2). These inhibitory events by DLC1 were RhoGAP-dependent, as RhoGAP-
deficient mutant of DLC1 (DLC1 K714E) abolished these inhibitory events. In addition, from western study, DLC1 inhibited
ROCK-related myosin light chain phosphatase targeting unit 1 (MYPT1) phosphorylation at Threonine 853. By examining cell
morphology under microscope, we found that ectopic expression of dominant-active ROCK released cells from DLC1-
induced cytoskeletal collapse and cell shrinkage.
Conclusion: Our data suggest that DLC1 negatively regulates Rho/ROCK/MLC2. This implicates a ROCK-mediated pathway
of DLC1 in suppressing metastasis of HCC cells and enriches our understanding in the molecular mechanisms involved in
the progression of hepatocellular carcinoma.
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Introduction
Cell migration involves cycles of steps which begin from the
formation of cell protrusion at the leading edge. At the sites of
protrusion, focal adhesions are formed to attach the cytoskeleton,
mainly actin and myosin, to the extracellular matrix. The
cytoskeleton generates tension which results in actomyosin
contractility to translocate the cell body. Finally, the tension
releases the adhesions from the cell’s trailing edge [1]. Deregu-
lation in any of the steps involved in cell migration can result in
aberrant cell movement and, in cancer cells, metastasis [2].
Hepatocellular carcinoma (HCC) is one of the most prevalent
cancers worldwide. Intrahepatic metastasis is the leading cause of
mortality in patients with this cancer. Therefore, we believe a
better understanding of the molecular mechanisms regulating
HCC cell migration may shed light to the development of novel
targeted therapeutic intervention.
Deleted in liver cancer 1 (DLC1), a tumor suppressor gene, was
first identified in primary HCC as a rat p122RhoGAP homolog
[3]. In HCC, DLC1 has been found to possess tumor suppressive
abilities [4–6] and is underexpressed mainly through gene deletion
and DNA methylation [7–9]. Underexpression of DLC1 is also
implicated in other cancers such as breast, lung, and prostate [9–
14]. DLC1 was also shown to be downregulated in metastatic cells
compared to non-metastatic cells in breast and HCC models
[15,16]. Ectopic expression of DLC1 was found to suppress cell
migration and invasion in HCC, non-small cell lung cancer, breast
cancer, lung cancer, ovarian cancer cell line models [4,15,17–21],
and overexpression of DLC1 in metastatic breast cancer cell line
could attenuate size and incidence of pulmonary metastases [15].
However, the molecular mechanisms underlying this suppression
of cell movement and cancer metastasis remain unclear.
DLC1 is a member of the RhoGTPase activating protein
(RhoGAP) family and possesses RhoGAP activity specific for
RhoA [8]. DLC1 negatively regulates the activity of RhoA by
enhancing intrinsic GTP hydrolytic activity of RhoA, thus
catalyzing the conversion of RhoA from its GTP-bound active
state to GDP-bound inactive state [22]. Rho-kinase (ROCK) is the
best known downstream effector of RhoA [23,24]. Binding of
RhoA releases ROCK from its autoinhibitory structure and
activates ROCK-mediated cellular events [23,25–27]. ROCK is
known to regulate cellular events related to cell motility. For
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Figure 1. DLC1 abolished ROCK-mediated stress fiber and focal adhesion formation. (A) ROCK inhibitor suppressed stress fiber and focal
adhesion formation in HCC cells. SMMC-7721 cells were seeded onto cover-slip one day before treatment. Stress fibers were stained with phalloidin
stain (red) and focal adhesions with paxillin stain (green). Stress fibers could be clearly observed as bundles stretching across the cells and focal
adhesions were attached to the stress fiber bundling arrays in SMMC-7721 mock treated control. Treatment with ROCK inhibitor Y27632 at 10 mM for
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example, ROCK was shown to control cell polarity by regulating
PTEN/Akt signaling pathway in neutrophils [28] and control tail
retraction in monocytes and prostate cancer cells [29–31]. ROCK
also enhanced actomyosin contractility, a principal step of cell
migration as described above [32]. Importantly, ROCK is a kinase
that phosphorylates and activates many downstream substrates
such as LIMK and myosin light chain 2 (MLC2). Phosphorylation
of these substrates is important in regulating cytoskeletal
reorganization and cell migration [33,34]. Hyperactivation of
the Rho/ROCK pathway is known to be associated with more
aggressive tumor properties such as metastasis and invasion [35–
41]. Deregulation of Rho/ROCK pathway may be consequen-
tially related to its aberrant upstream regulatory pathway. We
previously demonstrated that DLC1 is a RhoGAP protein and it is
therefore logical to speculate that DLC1 suppresses cancer cell
metastasis through negatively regulating ROCK-mediated cyto-
skeletal rearrangement. However, this hypothesis has never been
tested experimentally and the mechanistic basis of how DLC1
suppresses cancer cell metastasis has not been delineated. Hence, it
is strategic to examine the possible functional links between DLC1
and ROCK pathway and their implications in HCC.
In this study, we demonstrated that DLC1 inhibited ROCK-
mediated cytoskeletal events including formation of stress fiber and
focal contact network and phosphorylation of MLC2 at cell cortex.
Significantly, these inhibitory effects of DLC1 depended on its
RhoGAP activity. In addition, we have shown that DLC1
functioned as a negative regulator of ROCK in controlling cell
morphology. Overall, we demonstrated that DLC1 negatively
regulated ROCK in suppressing cell movement in HCC.
Results
DLC1 abolished formation of ROCK-mediated stress fiber
and focal adhesion network
First, we queried if the formation of stress fibers and focal adhesions
in HCC cells was ROCK dependent. We found that, the stress fiber
bundling arrays (stained with phalloidin stain) and focal adhesions
(paxillin), particularly those in the central region that were linked to
stress fibers, were abolished upon ROCK inhibitor treatment
(Figures 1A). This finding indicates that the formation of the stress
fibers and focal adhesions in HCC cells is ROCK-dependent.
To investigate the regulatory function of DLC1 on ROCK-
mediated stress fiber and focal adhesion formation in HCC, we
transiently overexpressed DLC1 in DLC1-deficient SMMC-7721
and BEL7402 HCC cells and its effects on the network of stress fibers
and focal adhesions were studied. Overexpression of wild-type DLC1
significantly suppressed formation of stress fibers and focal adhesions
in these cells, as indicated by phalloidin (Figure 1B) and paxillin stains
(Figure 1C-i and 1C-ii), respectively. Analogous to ROCK inhibition
(Figure 1A), DLC1 abolished mainly the stress fiber-linked focal
adhesions located in the central region of cells (Figure S1A). The loss
of focal adhesions was further aggravated with ectopic expression of
SAM domain-deleted mutant of DLC1 (DSAM) (Figure S1B), a
DLC1 truncated construct that caused a more severe cell shrinkage
and loss of stress fibers [4]. In contrast, a RhoGAP-deficient mutant
(DLC1 K714E) was unable to inhibit both stress fiber and focal
adhesion formation (Figures 1B and 1C). These findings demon-
strated that DLC1 inhibited ROCK dependent stress fiber and focal
adhesion formation via its RhoGAP activity.
DLC1 abolished ROCK-mediated cortical myosin light
chain 2 phosphorylation
Active ROCK specifically phosphorylates myosin light chain 2
(MLC2) at Ser 19; therefore, this ROCK-specific phosphorylation
has been widely used as a surrogate marker of ROCK activity
[36,42–45]. Phosphorylation of MLC2 at Ser19 is important for
the activity of myosin which is responsible for actomyosin
contractility and hence cell migration [46]. In this study, we
60 minutes suppressed formation of stress fiber and focal adhesion network in SMMC-7721. (B) and (C) DLC1 suppressed ROCK-mediated stress fiber
and focal adhesion formation in HCC cells. SMMC-7721 cells (i) and BEL7402 (ii) were transfected with myc-tagged expression plasmids, pCS2+MT,
pCS2+MT/DLC1, and pCS2+MT/DLC1 K714E, and recognized by anti-myc antibodies (9E10). Stress fibers and focal adhesions were stained with
phalloidin-TRITC and anti-paxillin antibody, respectively. Wild-type DLC1, but not RhoGAP-deficient mutant (DLC1 K714E), suppressed stress fibers
formation and reduced the number of stress fibers-linked focal adhesions formed in SMMC-7721 cells. Percentage of different DLC1 constructs
transfected cells exhibiting stress fibers or focal adhesions were presented in a bar graph accordingly. For each construct, total 67–170 transfected
cells were counted under microscope. Error bars represent standard deviation (SD) of data obtained from two independent experiments.
doi:10.1371/journal.pone.0002779.g001
Figure 2. ROCK-mediated cortical phosphorylation of MLC2. (A)
BEL4702 HCC cell line treated with mock control or ROCK inhibitor
(Y27632) was probed with mouse monoclonal antibody against
phospho-MLC2 (Ser 19). Phospho-MLC2 (green) was mainly detected
at the cell cortex of BEL7402 cells (as indicated by the arrows) and this
cortical staining pattern was abolished by treatment with ROCK
inhibitor Y27632. (B) BEL7402 cells were transfected with myc-tagged
dominant negative ROCK or dominant active ROCK constructs and
detected with rabbit polyclonal antibody against myc-epitope (A14)
(Red). Dominant active (DA) ROCK caused intense phosphorylation of
MLC2 (Ser 19) at the actin bundles (Precentage of cells exhibiting this
phenomenon: 94.0% of the DA ROCK-transfected cells compared to 0%
of the vector transfected cells). Arrows point at the actin bundles of the
dominant active ROCK transfected cell where phosphorylation of MLC2
(Ser 19) was enhanced. Dominant negative (DN) ROCK suppressed
cortical phosphorylation of MLC2 (Ser 19) (Percentage of cells exhibiting
this phenomenon: 87.5% of the DN ROCK-transfected cells compared to
7.3% of the vector transfected cells). Arrows point at the cell cortex of
the dominant negative ROCK transfected cell where phosphorylation of
MLC2 (Ser 19) was lost. As shown, a tight regulation and an optimal
level of ROCK activity were required to maintain cortical phosphory-
lation of MLC2 (Ser 19) in BEL7402 cells.
doi:10.1371/journal.pone.0002779.g002
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observed that phospho-MLC2 staining of BEL7402 HCC cells was
especially prominent at the cell cortex. However, when ROCK
activity was blocked either by Y27632 (Figure 2A) or ectopic
expression of a dominant-negative ROCK mutant (Figure 2B), this
peripheral phosphorylation of MLC2 was completely abolished
and the phosphorylation of MLC2 became a predominantly
cytoplasmic pattern. In contrast, ectopic expression of dominant-
active ROCK culminated in a substantial increase of MLC2
phosphorylation at actin bundles (Figure 2B). These findings
indicate that this distinctive phosphorylation pattern of MLC2 at
cell cortex is tightly and positively regulated by ROCK activity.
We next investigated whether DLC1 could abolish this ROCK-
specific MLC2 phosphorylation pattern in HCC cells. We first
evaluated whether the cortical phospho-MLC2 staining pattern
was related to the endogenous expression levels of DLC1 in
different cell lines. We observed conspicuous phospho-MLC2
staining at the cell cortex in SMMC-7721, BEL7402, and WRL
HCC cell lines (Figure 3C), and HeLa cervical cancer cell line
(Figure 3C), which had no expression of DLC1 (Figure 3A). On
the other hand, HepG2 and Hep3B, the two HCC cell lines with
DLC1 expression (Figure 3A), displayed diffuse cytoplasmic
phospho-MLC2 staining without any distinct cortical phosphor-
ylation of MLC2 at cell periphery (Figure 3B).
To verify that inhibition of cortical phospho-MLC2 was directly
related to DLC1, we then transiently expressed wild-type DLC1 and
DLC1 RhoGAP-deficient mutant (K714E), respectively, in DLC1-
null BEL7402 cells. Wildtype DLC1 substantially reduced the
number of cells having phospho-MLC2 cortical staining (Figures 4A
& 4B), signifying the suppressive role of DLC1 on ROCK activity.
On the other hand, DLC1 RhoGAP-deficient mutant (K714E) was
Figure 3. DLC1 expression was associated with cortical phosphorylation of MLC2. (A) DLC1 mRNA and protein expression in HCC cell lines.
(B) and (C) DLC1 expression was associated with phospho-MLC2 staining pattern. Representative pictures from DLC1-positive and DLC1-negative
cells, respectively. DLC1-positive Hep3B and HepG2, displayed diffuse phosphorylation of MLC2, whereas DLC1 non-expressing BEL7402 and HeLa,
displayed pronounced cortical phosphorylation of MLC2 at cell cortex.
doi:10.1371/journal.pone.0002779.g003
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unable to abolish phospho-MLC2 cortical staining (Figures 4A & 4B).
Our observation therefore suggested DLC1 inhibited ROCK-specific
MLC-2 phosphorylation in HCC cells, via its RhoGAP activity.
DLC1 attenuated myosin phosphatase activity by
reducing phosphorylation of myosin phosphatase target
subunit 1 (MYPT1) at Thr 853
Apart from phosphorylation of myosin, ROCK also increases
myosin phosphorylation by phosphorylating myosin phosphatase
target subunit 1 (MYPT1) at Thr 696 and Thr 853 and thereby
inactivating it. Although Thr 696 of MYPT1 can be phosphorylated
by other protein kinases, Thr 853 phosphorylation, on the other
hand, is selectively regulated by ROCK [32]. Moreover, MYPT1
Thr 853 phosphorylation has been shown to be a promising
surrogate marker that reversely correlates with myosin phosphatase
activity [36,42–45]. In this study, we found that, upon Y27632
treatment, the phosphorylation levels of MYPT1 (Thr 853) were
reduced in all HCC cell lines tested (Figure 5A), while the total
MYPT1 levels remained unchanged. Similarly, overexpression of
DLC1 attenuated phosphorylation of MYPT1 at Thr853, indicat-
ing the loss of ROCK activity (Figure 5B). Inactivation of myosin
phosphatase (as reflected by increased MYPT1 phosphorylation)
and activation of MLC2 are combined effects of ROCK, and these
effects could be suppressed by DLC1, leading to a total decrease of
myosin phosphorylation and a reduction of cell contractility.
ROCK inhibitor suppressed HCC cell motility
By ectopic expression of DLC1 in HCC cell line, we previously
showed that DLC1 significantly repressed HCC cell migration and
invasiveness [4]. To substantiate our hypothesis that DLC1
suppressed cell migration via negatively regulating ROCK
activity, we examined the effect of ROCK inhibitor on HCC cell
migration with transwell assay. We observed that the ROCK
inhibitor Y27632 suppressed migration of HCC cells, SMMC-
7721 (Figure 6A left panel) and BEL7402 (Figure 6B left panel), as
demonstrated by the decreased number of migrated cells in
transwell assay. This finding indicates that ROCK activity is
crucial for HCC cell migration. To eliminate any misinterpreta-
tion due to cell death caused by toxicity of the drug, we performed
cell proliferation assay on the HCC cells. Cell proliferation assay
demonstrated that Y27632 did not affect cell growth which
confirmed that inhibition of ROCK only affected HCC cell
migration (Figure 6A and 6B right panel).
ROCK reversed the cell morphological alteration of DLC1
We previously demonstrated that DLC1 was able to induce cell
morphological change with reduced stress fiber formation in HCC
cells and fibroblasts [4]. Since ROCK is a chief modulator in
cytoskeletal signaling and cytoskeletal organization is a key
determinant of cell morphology, we speculated that the cell
morphological changes induced by DLC1 were via ROCK. To
this end, we observed the cell morphology of DLC1 and ROCK
co-transfected cells by immunofluorescence staining. We also
counted the number of cells that exhibited cell collapse or
shrinkage caused by collapse of cytoskeletal network (Figure 7C),
as described elsewhere [4,47–49]. In this study, we observed that
overexpression of DLC1 in COS7 cells induced cytoskeletal
collapse or cell shrinkage (Figure 7A-i), similar to our previous
finding [4]. Cell shrinkage was intensified by ectopic expression of
SAM domain-deleted mutant of DLC1 (DSAM) (Figure 7B-i). Co-
transfection of empty pEGFP vector could not rescue DLC1-
induced cell morphological change, but cells with dominant active
ROCK could overcome the inhibitory regulation from DLC1
(Figure 7A-ii) and even DLC1DSAM (Figure 7B-ii) and released
cells from DLC1-induced cell shrinkage. This experiment showed
that ROCK is one of the downstream effectors of DLC1 in
coordinating the morphological changes in HCC cells.
Discussion
One of the important roles of DLC1 is its ability in repressing
cancer cell migration and invasion. In this study to elucidate the
underlying mechanisms in the regulation of HCC cell migration
and invasion by DLC1, we have shown that DLC1 suppressed
HCC cell migration through regulating the cytoskeleton and
actomyosin contraction. Also, we have shown that DLC1
functioned as a negative regulator of ROCK in controlling cell
morphology.
Figure 4. DLC1 RhoGAP was responsible for regulating cortical
phosphorylation of MLC2. (A) pCS2+MT vector alone, pCS2+MT
DLC1, and pCS2+MT DLC1 K714E, respectively, were transfected into
BEL7402 cells. Recognition of transfected cells was done by probing
cells with c-myc (A14) rabbit antibody followed by staining with anti-
rabbit antibody conjugated with Texas Red. Cells transfected with
pCS2+MT vector alone displayed pronounced cortical phosphorylation
of MLC2 as indicated by the arrows. Cells transfected with DLC1
displayed loss of cortical phosphorylation of MLC2. Cells transfected
with DLC1 K714E, the RhoGAP-deficient mutant, still displayed
pronounced cortical phosphorylation of MLC2 as indicated by the
arrows. (B) Percentage of different DLC1 constructs exhibiting cortical
phosphorylation of MLC2 at Ser 19 was calculated and presented in a
bar graph. For each construct, 80–100 transfected cells were counted
and cortical MLC2 phosphorylation was recorded. Error bars represent
standard deviation (SD) of data obtained from three independent
experiments.
doi:10.1371/journal.pone.0002779.g004
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DLC1 negatively regulated ROCK mediated actomyosin
contractility
The contractile motion of cancer cells is generated by consecutive
contractions of actomyosin bundles composed of actin and myosin
called actomyosin. These actomyosin bundles, visualized as stress
fibers, stretch across the cell body and create a tension to generate
cell contraction to drive cell movement by connecting with the focal
adhesion molecules [50]. Based on the previous study on the
inhibitory effect of DLC1 on stress fibers, herein we further found
that the formation of stress fibers and focal adhesions network was
dependent on DLC1 RhoGAP and ROCK activity in HCC cells.
This finding further elucidates that stress fibers and focal adhesions
work hand in hand as described byHall A. [51], and their formation
is interdependent and tightly regulated by RhoGAP of DLC1 and
ROCK activity. In addition, DLC1 decreased ROCK-mediated
phosphorylation of MYPT1 (Thr853) and phosphorylation of
MLC2 (Ser19) and would consequently lead to a decrease of total
myosin phosphorylation and cause a reduction of stress fiber
contractility [46]. All these lines of evidence converged to explain
that DLC1 controlled one of the pivotal migratory mechanisms,
actomyosin contraction, similar to another member of the RhoGAP
family, p190-RhoGAP [52].
DLC1 abolished focal adhesion formation and also
localized to focal adhesion complex
An intriguing issue of this finding about the inhibitory effect of
RhoGAP on focal adhesion molecules has arisen. DLC1 and
several members of the RhoGAP proteins including p122-
RhoGAP and RC-GAP72 were found to be localized at the focal
adhesions [47,49]. In fact, others and we have previously reported
that DLC1 also localized to focal adhesions and interacted with
members of the tensin family [18,53,54]. In this study, we found
that DLC1 suppressed stress fiber-linked focal adhesion formation
by its RhoGAP activity. From immunofluorescence study, we
observed that, in a portion of DLC1 transfected cells, DLC1
exhibited a focal adhesion localization pattern (Figure S1A);
whereas in some other DLC1 transfected cells, especially those
displaying extensive cell shrinkage, an intensive loss of stress fiber-
linked focal adhesions was observed (Fig. 1C). DLC1 localization
to focal adhesions and its inhibitory effect on focal adhesions are
not mutually exclusive. We speculate that dosage effect might be
one of the factors involved. When a cell was transfected with a
high dose of DLC1, DLC1 would extinguish all the stress fibers
and the stress fiber-linked focal adhesions and result in extensive
cell collapse (Fig. 1C). On the other hand, when a cell was
transfected with a lower dose of DLC1, DLC1 would extinguish
most of the stress fibers and stress fiber-linked focal adhesions but
spare some focal adhesions not linked to stress fibers and result in a
milder cell collapse (Figure S1A). Another speculation was that
similar to RC-GAP72 [47], DLC1 might localize to focal adhesion
to disintegrate the focal adhesion complexes.
Cytoskeletal collapse induced cell shrinkage and the
impact of DLC1 on cytoskeletal collapse
Focal adhesions and actomyosin stress fibers always work in
inter-dependent manner and they together construct a scaffold to
Figure 5. DLC1 and ROCK regulated MYPT phosphorylation. (A) ROCK inhibitor Y27632 suppressed MYPT phosphorylation at Thr 853 in all
HCC cell lines. (B) DLC1 suppressed MYPT phosphorylation at Thr 853 in 293 T cells. Band intensity was analyzed by AlphaEaseFCTM and percentage
was calculated from comparison with its according control.
doi:10.1371/journal.pone.0002779.g005
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support an intact morphology of the cell [47]. The disruptions of
the abovementioned network caused by DLC1 led to an intensive
cell cytoskeletal collapse resulting in cell shrinkage. This finding
was similar to Barberis D et al.’s study on p190RhoGAP that loss of
focal adhesions induced by p190RhoGAP preceded cell shrinkage
[48]. We observed that loss of focal adhesions and stress fibers took
place an hour after ROCK inhibition by Y27632, but cells did not
collapse immediately (Figure 1A) until prolonged treatment of
Y27632 up to 24 hours (Figure S2). From this observation, we
conjecture that cell collapse caused by Y27632 treatment was
ensued from loss of focal adhesion and stress fiber network. Upon
inhibition of ROCK by Y27632, the cytoskeletal networks could
not be formed and the cells could no longer endure the loss of
cytoskeletal network and eventually undergo cell collapse, which
we observed as cell shrinkage (Figure 8). The present study showed
that the cytoskeletal collapse induced by DLC1, a RhoGAP which
its downregulation is associated with HCC progression, could be
partially reversed by active ROCK, further implying that DLC1
negatively regulated ROCK in controlling actomyosin contractil-
ity, cell morphology, and cell migration sequentially. Our previous
study reported that DLC1 not only suppressed cell migration but
also cell invasion which involved extracellular matrix barrier.
Sahai E et al. reported that cancer cell lines might possess different
modes of cell motility and the rounded morphology cancer cell
lines were more sensitive to ROCK inhibitor in 3-dimensional
matrix [55]. However, whether this model is applicable to HCC
cells and whether other extracellular proteolytic pathways
coorperate with the DLC1/Rho/ROCK/MLC pathway are still
unknown and awaited to be addressed.
Our study demonstrated that ROCK inhibitor, Y27632, did not
affect HCC cell proliferation at an efficient dosage that suppressed
HCC cell migration. ROCK inhibitors have been widely used in
animal models, such as rat and mice models, without causing
major toxicity to the animals at efficient dosages [35,56].
Takamura et al. demonstrated that Y27632 could inhibit
intrahepatic metastasis of HCC [35] and recently, another ROCK
Figure 6. ROCK inhibitor suppressed HCC cell migration. ROCK inhibitor Y27632 suppressed HCC cell migration. Y27632 decreased number of
migrated (A) SMMC-7721 cells (P,0.0001, t-test) and (B) BEL7402 cells (P,0.0001, t-test). Error bars represent standard deviation (SD) of data
obtained from three microscopic fields. Experiments have been repeated three times. Cell proliferation assay was shown on the right to compare
growth rate of mock control cells and Y27632 treated cells.
doi:10.1371/journal.pone.0002779.g006
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inhibitor, fasudil, has been successfully applied in clinical trial for
patients with cardiovascular diseases [57]. These studies demon-
strate that the toxicity of ROCK inhibitors to cells is limited [35].
Accumulating knowledge indicates that ROCK is playing an
important role in cancer metastasis, and the present study has
enriched the knowledge on the ROCK signaling pathway in
HCC. ROCK inhibitors such as Y27632 might be useful to the
chemotherapeutic intervention in suppressing intrahepatic metas-
tasis, a major cause of mortality in HCC patients, without causing
much adverse effects to the patients. Further characterization of
the efficacies of ROCK inhibitors and anti-ROCK therapies in
the treatment of HCC is still awaited.
Materials and Methods
Cell lines and plasmids
SMMC-7721 and BEL7402 were gifts from Shanghai Institute
of Cell Biology, Chinese Academy of Sciences; 293T, COS7,
HepG2 and Hep3B were obtained from American Type Culture
Collection (Manassas, VA). 293T, BEL7402, SMMC-7721, and
COS7 were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) high glucose supplemented with 10% fetal bovine serum;
Hep3B and HepG2 were cultured in minimum essential medium
(MEM) supplemented with 10% fetal bovine serum. Myc-tagged
expression constructs (pCAG) carrying human wild-type ROCK,
dominant active ROCK (1–725 a.a.), and dominant negative
ROCK mutant (K105A, I1009A) were kindly provided by S.
Narumiya (Faculty of Medicine, Kyoto University) [27]. The
human ROCK kinase domain (ROCK 76–338 a.a.) was PCR
amplified and cloned into pEGFPC3 vector using KpnI and XhoI
digestion sites and was used as dominant active form of ROCK.
Wild-type DLC1 and RhoGAP-deficient mutants were cloned as
described previously [4].
Drug treatment and transfection
ROCK-specific inhibitor Y27632 was obtained from Calbio-
chem (Darmstadt, Germany). For treatment, cells were added
Y27632 at 10 mM and incubated for 1 hour at 37uC. For
transfection, 16105 cells were seeded on coverslips in 35-mm
plates one day before transfection. Indicated plasmids were
transfected into cells with FuGene 6 reagent (Roche, Basel,
Switzerland) according to manufacturer’s instructions.
Immunofluorescence microscopy
Mouse monoclonal antibody against phospho-myosin light chain
2 (Ser 19) was purchased from Cell Signaling Technology (Danvers,
MA). Mouse monoclonal antibody against paxillin was obtained
from Upstate (Lake Placid, NY). Mouse monoclonal (9E10) and
rabbit polyclonal (A14) antibodies against c-myc were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Texas Red dye-
conjugated AffiniPure goat anti-mouse IgG and fluorescein (FITC)-
conjugated AffiniPure goat anti-rabbit IgG were purchased from
Jackson Immuno Research Laboratories (West Grove, PA). For
immunofluorescence staining, cells were fixed in paraformaldehyde,
permeabilized with TritonX, blocked with bovine serum albumin
and then incubated with indicated primary and secondary
antibodies. Focal adhesions were probed with anti-paxillin antibody
and stress fibers were stained with phalloidin TRITC (Sigma
Aldrich, St. Louis, MO). Nuclear counterstaining was done with 49-
6-Diamidino-2-phenylindole (DAPI) (Calbiochem, San Diego, CA)
and coverslips were mounted in Vectashield antifade mountant
(Vector Laboratories, Burlingame, CA). Cells were counted under
Leica Q550CW fluorescence microscope (61,000 magnification)
and images were captured with a charge-coupled device camera
connected to the microscope.
Cell migration assay
Transwell assay was performed with Transwell Boyden
chamber of polycarbonate membranes with pore size of 8.0 mm
(Corning Inc., NY). 56104 cells resuspended in serum free culture
medium were added to the upper chamber whilst culture medium
with 10% FBS was placed in the lower chamber as chemoat-
tractant. Cells were incubated in CO2 incubator at 37uC. Cells
having migrated through the pores to the lower surface of the
membrane were fixed with methanol and stained with crystal
violet. Photographs of 3 different fields of the stained cells were
Figure 7. ROCK reversed the cell morphological alteration of
DLC1. COS7 cells were co-transfected with (A) DLC1 and ROCK or (B)
DLC1DSAM and ROCK, respectively. Cells transfected with pCS2MT
DLC1 or pCS2MT DLC1DSAM appeared red, while cells transfected with
pEGFP or pEGFP ROCK appeared green. DLC1-induced cell cytoskeletal
collapse or cell shrinkage (A-i), which was further enhanced and clearly
demonstrated by SAM-deleted construct, pCS2+MT DLC1DSAM (B-i).
ROCK was able to restore cells from DLC1-induced cell shrinkage (A-ii)
and even from DLC1DSAM-induced intense cell shrinkage (B-ii). (C) Co-
transfected cells were counted and their morphologies recorded. The
number of co-transfected cells displaying observable cell shrinkage (cell
collapse) was divided by total number of co-transfected cells counted,
to calculate the percentage of cells in displaying shrinkage as shown in
the bar graph. For each column, 150–200 co-transfected cells were
counted. Error bars represent standard deviation (SD) of data obtained
from three independent experiments.
doi:10.1371/journal.pone.0002779.g007
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captured and cells were counted. Experiment was repeated
independently three times.
Cell proliferation assay
26104 cells were seeded in 12 well plates. Cells were counted
everyday with COULTER COUNTERH Cell and Particle
Counter (Beckman Coulter) in triplicates and a 6-day growth
curve was plotted. Cells were replenished with fresh medium
(mock or Y27632) every other day.
mRNA extraction, protein extraction and western blots
Total RNA was extracted by TRIZOL reagent, cDNA was
synthesized, and the expression of DLC1 mRNA and GAPDH
was detected by RT-PCR with specific primers as described
previously [8]. For Western blot, cells were lysed with SDS buffer
or NP40 in NET buffer. Proteins were resolved by SDS-PAGE
and blotted onto a nitrocellulose membrane. The membrane was
probed using anti-DLC1 antibody (BD Biosciences Pharmingen),
anti-MYPT antibody or anti-phospho-MYPT (Thr853) antibody
(Upstate), followed by incubation with anti-mouse IgG or anti-
rabbit IgG (GE Healthcare, Buckinghamshire, UK). Protein
expression was detected with the ECLTM detection system (GE
Healthcare) according to the manufacturer’s protocol. Images
were scanned and intensity of bands was quantified with
AlphaEaseFCTM software.
Supporting Information
Figure S1 Effect of DLC1 on focal adhesions.
Found at: doi:10.1371/journal.pone.0002779.s001 (0.28 MB
PDF)
Figure S2 Prolonged ROCK inhibitor treatment induced HCC
cell collapse.
Found at: doi:10.1371/journal.pone.0002779.s002 (0.29 MB
PDF)
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